Viscosupplementation for Knee Osteoarthritis
Customize your policy alerts
Sign up for all medstarfamilychoicedistrictofcolumbia policy alerts
Know when medstarfamilychoicedistrictofcolumbia releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs medical necessity, coverage, and prior authorization requirements for intra-articular hyaluronic acid (viscosupplementation) injections for members with knee osteoarthritis enrolled in MedStar Family Choice District of Columbia.
New policy establishing medical necessity criteria and preferred products for viscosupplementation for knee osteoarthritis.
Coverage Criteria for Viscosupplementation
Initial Approval
Covered when ALL of the following are met
See documentation requirements for required supporting chart notes
Requests for treatment when TKR is planned within 6 months are not covered
Reauthorization
Covered for reauthorization when ALL of the following are met
Documentation must be available for review
Minimum interval between treatment courses per knee is no more often than every 6 months
Product and Indication Restrictions
Coverage is limited and other uses are restricted
Prior authorization required for non-preferred products; see coding for HCPCS/CPT codes
Administration CPT code: 20610
Viscosupplementation for indications other than knee osteoarthritis is considered experimental, investigational, or unproven because effectiveness for these other uses has not been established in improving health outcomes.
Coverage is limited to the specified preferred products: Durolane, Gel-One, and Euflexxa. All other viscosupplementation products are non-preferred and are not covered unless medical necessity is demonstrated and prior authorization is approved. Requests for non-preferred products should include documentation supporting medical necessity per prior authorization requirements (see required documentation and clinical criteria).
Coding and Treatment Interval Rules
Provider Requirements, Prior Authorization, and Documentation
Prior authorization required for non-preferred products
Prior authorization is required for non-preferred viscosupplementation products; coverage is limited to the preferred products Durolane, Gel-One, and Euflexxa. Requests for other products will only be considered if medical necessity is demonstrated and a prior authorization is approved.
- Preferred products: Durolane, Gel‑One, Euflexxa
- Non-preferred products are not covered without approved prior authorization and demonstrated medical necessity
Required conservative therapy and pharmacologic trials before viscosupplementation
Member must have had inadequate relief with non‑pharmacologic therapies (physical therapy, brace, weight loss, regular exercise) and must have inadequate response, intolerance, or contraindication to analgesics for at least 3 months and to intra‑articular steroid injections for at least 3 months prior to approval.
- Non‑pharmacologic trial: physical therapy, brace, weight loss, regular exercise — inadequate relief required
- Analgesic trial: ≥3 months (e.g., NSAIDs, acetaminophen up to 3–4 g/day) — inadequate response/intolerance/contraindication
- Intra‑articular steroid trial: ≥3 months — inadequate response/intolerance/contraindication
Required documentation to support medical necessity
Chart notes must document diagnosis of knee osteoarthritis confirmed by radiographic findings OR at least five specified clinical signs/symptoms, functional impact, prior therapy trials, and timing relative to prior treatments or planned surgery as required for initial approval and reauthorization.
- Radiographic confirmation: joint space narrowing, subchondral sclerosis, osteophytes, or subchondral cysts OR ≥5 of the listed clinical criteria (bony enlargement, bony tenderness, crepitus, ESR <40 mm/hr, morning stiffness <30 min, no palpable synovial warmth, age >50, RF <1:40, synovial fluid clear/normal viscosity and WBC <2000/mm3)
- Document inadequate relief from non‑pharmacologic therapies and trials of analgesics (≥3 months) and intra‑articular steroids (≥3 months)
- For reauthorization, document significant clinical improvement after prior injection and recurrence of symptoms with ≥6 months elapsed since prior treatment
- Document that the member is not scheduled for total knee replacement within 6 months
Denial triggers for viscosupplementation requests
Requests for non‑preferred viscosupplementation products are not covered unless medical necessity is demonstrated and prior authorization is approved; additional denial triggers include lack of documented trials of required conservative therapies, inadequate documentation of radiographic OA or qualifying signs/symptoms, or planned total knee replacement within 6 months.
- Non‑preferred products without approved PA and demonstrated medical necessity will be denied
- Denial likely if chart lacks required conservative therapy trials or required radiographic/clinical documentation
- Denial likely if member is scheduled for total knee replacement within 6 months
Definitions and Imaging Criteria
Background
Viscosupplementation refers to intra-articular injections of hyaluronic acid administered into the knee joint to provide symptomatic relief for knee osteoarthritis. This policy establishes medical necessity criteria, preferred products, dosing/frequency limits, and prior authorization requirements to ensure appropriate, evidence-based use. Coverage is limited to the preferred products Durolane, Gel-One, and Euflexxa, and treatment is authorized only when clinical and radiographic criteria are met, conservative therapies and specified pharmacologic trials have failed or are contraindicated, and the member is not scheduled for total knee replacement within 6 months. Dosing regimens and the minimum interval between treatment courses of no more often than every 6 months per knee are specified for each product.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.